Related Experiment Video
Updated: Jun 4, 2025
05:31
Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
755
Reduced AT2R Signaling Contributes to Endothelial Dysfunction After Preeclampsia
Kelsey S Schwartz1, Mingyao Sun2, Diana I Jalal3,2
1Department of Health and Human Physiology, The University of Iowa (K.S.S., A.E.S.).
Hypertension (Dallas, Tex. : 1979)
|December 26, 2024
Summary
Women with a history of preeclampsia have reduced Ang II type 2 receptor (AT2R) mediated dilation, contributing to endothelial dysfunction. Acute AT2R activation may improve microvascular function postpartum in these women.
Area of Science:
- Cardiovascular Science
- Reproductive Endocrinology
- Vascular Biology
Background:
- Preeclampsia history increases cardiovascular disease risk.
- Postpartum vascular endothelial dysfunction persists.
- The role of Ang II type 2 receptors (AT2R) in this dysfunction is unclear.
Purpose of the Study:
- To investigate the functional role of AT2R in postpartum microvasculature.
- To determine if AT2R activation improves endothelial function after preeclampsia.
Main Methods:
- Studied 24 women (12 preeclampsia, 12 healthy pregnancy history).
- Measured cutaneous vascular conductance responses to AT2R agonist (compound 21) and NO synthase inhibition.
- Quantified endothelial AT1R and AT2R expression via immunofluorescence.
Main Results:
- AT2R-mediated dilation and NO-dependent contribution were reduced in women with preeclampsia history.
- Endothelial AT2R expression was lower in women with preeclampsia history.
- Acute AT2R activation improved endothelial and NO-dependent dilation in women with preeclampsia history.
Conclusions:
- Reduced AT2R-mediated dilation contributes to postpartum endothelial dysfunction after preeclampsia.
- AT2R activation may enhance endothelial function via NO-dependent pathways in women with preeclampsia history.
Related Concept Videos
01:33Hormonal Regulation
32.9K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.9K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
580
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
580
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
473
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
473
01:25Antihypertensive Drugs: Direct Renin Inhibitors
487
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
487
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
135
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
382
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382